User profiles for Kirsten C Morley

Kirsten Morley

Sydney University
Verified email at sydney.edu.au
Cited by 3474

Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi‐centre, randomized, double‐blind, placebo‐controlled trial

KC Morley, M Teesson, SC Reid, C Sannibale… - …, 2006 - Wiley Online Library
Aim To compare the efficacy of acamprosate and naltrexone in the treatment of alcohol
dependence. Design A double‐blind, placebo‐controlled trial. Setting Three treatment centres in …

Baclofen for the treatment of alcohol use disorder: the Cagliari Statement

…, P Jaury, AR Lingford-Hughes, KC Morley… - The Lancet …, 2018 - thelancet.com
Alcohol use disorder is a leading cause of morbidity and mortality. 1–2 Alcohol consumption
is related to approximately 4% of the global burden of disease. 1 In clinical settings and …

New Australian guidelines for the treatment of alcohol problems: an overview of recommendations

…, K Butler, J Connor, KC Morley - Medical Journal of …, 2021 - Wiley Online Library
… For screening in the general community, the AUDIT‐C is a suitable alternative (Level A). …
varenicline may help support reduction of both tobacco and alcohol consumption (Level C). …

Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial

KC Morley, A Baillie, I Fraser… - The British Journal of …, 2018 - cambridge.org
BackgroundThere are no available medications for the management of alcohol dependence
for patients with alcoholic liver disease (ALD).AimsTo conduct a multisite, double blind, …

Alcohol use disorder and circulating cytokines: A systematic review and meta-analysis

…, JH Conigrave, J Lewohl, P Haber, KC Morley - Brain, Behavior, and …, 2020 - Elsevier
There has been emerging interest in the role of the immune system in the pathophysiology
of alcohol use disorder (AUD) given alcohol consumption stimulates immune cells to secrete …

Pharmacotherapeutic agents in the treatment of methamphetamine dependence

KC Morley, JL Cornish, A Faingold… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Methamphetamine use is a serious public health concern in many countries
and is second to cannabis as the most widely abused illicit drug in the world. Effective …

Increased anxiety and impaired memory in rats 3 months after administration of 3, 4-methylenedioxymethamphetamine (“ecstasy”)

KC Morley, JE Gallate, GE Hunt, PE Mallet… - European journal of …, 2001 - Elsevier
Male Wistar rats were administered either (a) a high dose regime of 3,4-methylenedioxymethamphetamine
(MDMA) (4×5 mg/kg, ip over 4 h on each of 2 consecutive days), (b) a …

The role of clinical champions in facilitating the use of evidence-based practice in drug and alcohol and mental health settings: a systematic review

…, KS Lee, PS Haber, KC Morley - Implementation …, 2020 - journals.sagepub.com
Background: The dissemination and adoption of research into clinical practice in health care
settings is a complex and challenging process. Clinical champions have been increasingly …

[HTML][HTML] The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective

…, P Jaury, AR Lingford-Hughes, KC Morley… - Frontiers in …, 2019 - frontiersin.org
Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and
morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABA-B) receptor …

Serotonin (1A) receptor involvement in acute 3, 4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat

KC Morley, JC Arnold, IS McGregor - Progress in Neuro …, 2005 - Elsevier
… Five minutes before testing, rats were placed in holding cages (40 × 25 × 15 cm opaque
box lined with bedding) in the testing room, which was heated to 28 C. Previous research has …